Otsuka American Pharmaceutical, Inc. (OAPI) has announced the appointment of Mark Altmeyer to president and CEO. Altmeyer succeeds interim president and CEO Dean Haubrich, who has lead the company since Aug. 1, 2008. Haubrich has been named chairman of the OAPI's board. Altmeyer was most recently SVP, global commercialization for oncology at Bristol-Myers Squibb.
Cambridge, Massachusetts-based Genocea Biosciences, a vaccine discovery and development company, announced the hiring of Jane Halpern as vice president, regulatory affairs. Halpern was most recently director of regulatory affairs and head of technical regulatory affairs, North America, for GlaxoSmithKline Biologicals.